New Treatment Promising For Ulcerative Colitis SufferersJanuary 04, 2006For people with the chronic disease ulcerative colitis, life can be limited to few social functions and trips away from home. A promising new therapy pioneered by University of Kentucky gastroenterology specialists may offer improved lives to patients suffering from moderate to severe forms of the disease. Ulcerative colitis causes inflammation and ulcers in the colon, leading to abdominal pain and such frequent trips to the bathroom that normal routines can be disrupted. Finding the right treatment can be difficult, with therapies that may include steroids and anti-inflammatory drugs, or possibly surgery in as many as 25 to 40 percent of ulcerative colitis patients. A drug already used for other inflammatory diseases, including Crohn's and rheumatoid arthritis, has received FDA approval for treatment of ulcerative colitis after performing well in clinical trials. UK was a primary investigator of infliximab, brand name Remicade®, and enrolled the largest study group in North America. "It's a very welcome addition to our treatment options," said Willem J.S. deVilliers, M.D., Ph.D., chief of the UK Division of Digestive Diseases and Nutrition. DeVilliers co-authored a report of the trial, which was recently published in the New England Journal of Medicine. One of the study participants is Robert Lewandowski, of Hager Hill in Johnson County. Lewandowski was diagnosed with the disease a decade ago and saw the retirement plans he and his wife made slipping away as he became more and more reluctant to leave home. "The first thing you do is when you think about going somewhere, you have to think about where the bathroom is and how quickly you can get to it," Lewandowski said. "Eventually, you stop going and doing things because it's too much of a problem." Lewandowski's disease went into remission after a few years, then reappeared, sending him to the bathroom 20 or more times a day. Therapies he used in the past didn't work, so his physician referred him to the clinical study at UK. He saw an improvement almost immediately, and a year later, he is able to lead a normal life, with no symptoms of the disease. "I'm happy," he said. The medication is administered intravenously, with an initial regimen of three doses of infliximab, followed by maintenance infusions every eight weeks. Nearly 70 percent of patients receiving the drug experienced clinical response and remission early in the trial, and nearly all had significant results after one year of therapy. For more information, contact the UK Division of Digestive Diseases and Nutrition at (859) 323-5575. Written by: Beth Goins University of Kentucky |
|||||||||||||||||||||
| Related Ulcerative Colitis Current Events and Ulcerative Colitis News Articles Largest gene study of childhood IBD identifies 5 new genes In the largest, most comprehensive genetic analysis of childhood-onset inflammatory bowel disease (IBD), an international research team has identified five new gene regions, including one involved in a biological pathway that helps drive the painful inflammation of the digestive tract that characterizes the disease. M. D. Anderson redefines screening guidelines for breast, cervical and colorectal cancers Drawing on years of experience in cancer research and patient care, The University of Texas M. D. Anderson Cancer Center released today the most comprehensive, risk-based screening guidelines publicly available to date for breast, cervical and colorectal cancers. Probiotic Found to Be Effective Treatment for Colitis In Mice The probiotic, Bacillus polyfermenticus, can help mice recover from colitis, a new study has found. Discovery of genetic defect may lead to better treatments for common gut diseases New findings related to an uncommon genetic disorder may impact the diagnosis and treatment of inflammatory bowel disease (IBD), the most common chronic gastrointestinal illness in children and teens. Two million Americans have IBD which involves inflammation of the gastrointestinal tract. Oxidized form of a common vitamin may bring relief for ulcerative colitis New research published in the Journal of Leukocyte Biology finds retinoic acid may alleviate ulcerative colitis and similar irritable bowel diseases. Promising new target emerges for autoimmune diseases University of Michigan scientists say they have uncovered a fundamentally new mechanism that holds in check aggressive immune cells that can attack the body's own cells. Subclinical markers predict relapse in juvenile idiopathic arthritis post methotrexate withdrawal Elevated levels of the inflammatory biomarkers Myeloid Related Protein (MRP) 8/14 predict an increased risk of relapse following withdrawal of methotrexate (MTX) therapy in children with juvenile idiopathic arthritis (JIA) who have achieved inactive disease status. Electronic Pill Shows Its Smarts by Measuring pH Levels in Digestive Tract An electronic diagnostic tool called the SmartPill is swallowed by patients in order to take measurements as it travels through the gastrointestinal tract. Enzyme involved in inflammatory bowel disease discovered at Penn State College of Medicine Researchers at Penn State College of Medicine, working with biochemists, geneticists and clinicians at the University of Bern, Switzerland and in the United Kingdom, have discovered an enzyme that has a key role in inflammatory bowel disease (IBD). UCLA cancer researchers first to link intestinal inflammation with systemic chromosome damage UCLA scientists have linked for the first time intestinal inflammation with systemic chromosome damage in mice, a finding that may lead to the early identification and treatment of human inflammatory disorders. More Ulcerative Colitis Current Events and Ulcerative Colitis News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||